
    
      Study duration will be of minimum 2 years and up to 4 years. If after 4 years since the
      beginning of the study eliglustat is not approved and available to patients in participating
      country, patients in this country may continue to receive study treatment until eliglustat is
      available to patients through the compassionate use (expanded access) program or is approved
      and available through reimbursement, whichever comes first.
    
  